A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: Challenges and implications

Drug Metabolism Reviews

Volumn 40, Issue 2, 2008, Pages 377-401

  Garrison Jr , Louis P ^a   Carlson, Rick J ^a   Carlson, Josh J ^a   Kuszler, Patricia C ^a   Meckley, Lisa M ^a   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Economics; Equity; Gene patents; Genetic discrimination; Pharmacogenomics; Public policy; Regulation

Indexed keywords

MERCAPTOPURINE; ORPHAN DRUG; TRASTUZUMAB; WARFARIN;

COMMERCIAL PHENOMENA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEALTH CARE FINANCING; HUMAN; INFORMED CONSENT; LABORATORY TEST; MEDICAL LIABILITY; PHARMACIST; PHARMACOGENOMICS; POLICY; PRIVACY; REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; UNITED STATES; DRUG APPROVAL; DRUG COST; DRUG DESIGN; ECONOMICS; FINANCIAL MANAGEMENT; GENETIC PRIVACY; GENETIC SCREENING; GOVERNMENT REGULATION; HEREDITY; LEGAL ASPECT; PHARMACOGENETICS; SAFETY;

CONSUMER PRODUCT SAFETY; DRUG APPROVAL; DRUG COSTS; DRUG DESIGN; GENETIC DETERMINISM; GENETIC PRIVACY; GENETIC SCREENING; GOVERNMENT REGULATION; HUMANS; INFORMED CONSENT; INSURANCE, HEALTH, REIMBURSEMENT; MARKETING OF HEALTH SERVICES; PHARMACOGENETICS; PUBLIC POLICY; UNITED STATES;

EID: 44649187964     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530801952500     Document Type: Review

References (57)

1. Almarsdottir, A. B., Bjornsdottir, I., Traulsen, J. M. (2005). A lay prescription for tailor-made drugs - focus group reflections on pharmacogenomics. Health Policy 71:233-241.
2. Berman, J. J., Moore, G. W., Hutchins, G. M. (1998). U.S. Senate bill 422: The genetic confidentiality and nondiscrimination act of 1997. Diagn. Mol. Pathol. 7:192-196.
3. Bevan, J. L., Lynch, J. A., Dubriwny, T. N., Harris, T. M., Achter, P. J., Reeder, A. L., et al. (2003). Informed lay preferences for delivery of racially varied pharmacogenomics. Genet Med 5:393-399.
4. Blue Cross Blue Shield Association. (2003). Medical technology as a driver of healthcare costs: Diagnostic imaging. Retrieved 8/31/2005 from http://www.bcbs.com/coststudies/reports/Medical_Tech_Drivr_Rept_10.pdf
5. Bookman, E. B., Langehorne, A. A., Eckfeldt, J. H., Glass, K. C., Jarvik, G. P., Klag, M., et al. (2006). Reporting genetic results in research studies: Summary and recommendations of an NHLBI working group. American Journal of Medical Genetics Part A 140A:1033-1040.
6. Borchardt, P., Fernandez, D. (2005). Pharmacogenomics: An in-house advantage? Retrieved 2/15/2006 from http://pharmalicensing.com/articles/disp/ 1133196003_438b32e3548ea.
7. Botkin, J. R., Smith, K. R., Croyle, R. T., Baty, B. J., Wylie, J. E., Dutson, D., et al. (2003). Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118:201-209.
8. Buchanan, A., Califano, A., Kahn, J., McPherson, E., Robertson, J., Brody, B. (2002). Pharmacogenetics: Ethical issues and policy options. Kennedy Inst. Ethics J. 12:1-15.
9. Canterbury v. Spence, 464 F 2d 772 (D.C. Cir. 1972).
10. Centers for Disease Control and Prevention. (2006a). Evaluation of genomic applications in practice and prevention (EGAPP): Implementation and evaluation of a model approach. Retrieved 2/19/2006 from http://www.cdc.gov/ genomics/gtesting/egapp.htm.
11. Centers for Disease Control and Prevention. (2006b). Genomics and disease prevention: Evaluation of genetic testing. Retrieved 3/27/2006 from http://www.cdc.gov/genomics/gtesting/EGAPP/docs/news_2005_sep.htm.
12. Clark, J., Piccolo, J., Stanton, B., Tyson, K. (2000). Patent pools: A solution to the problem of access in biotechnology patents? In United States Patent and Trademark Office (Ed.).
13. Diamond v. Chakrabarty, 447 U.S 303 (1980).
14. DiMasi, J. (2001). Risks in new drug development: Approval success rates for investigational drugs. Clinical Pharmacology & Therapeutics 69:297.
15. Food and Drug Administration. (1999). Guidance for industry: Consumer-directed broadcast advertisements. Retrieved 2/19/06 from http://www.fda.gov/cder/Guidance/1804fnl.htm.
16. Food and Drug Administration. (2005a). Evaluating the risks of drug exposure in human pregnancies.
17. Food and Drug Administration. (2005b). Guidance for industry development and use of risk minimization action plans.
18. Food and Drug Administration. (2005c). Guidance for industry premarketing risk assessment.
19. FDAAdvisoryCommittee.com. (2003). Pharmacogenetic data with clinical consequences should be described in labeling. Retrieved 2/15/2006 from http://www.fdaadvisorycommittee.com/FDC/AdvisoryCommittee/Committees/ Pharmaceutical+Science/042303_pharmacogenetics/042303_PharmacogeneticsR.htm.
20. Garrison, L. P., Jr., Austin, M. J. F. (2006). Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Aff. (Millwood). 25:1281-1290.
21. Garrison, L. P., Jr., Austin, M. J. F. (2007). The economics of personalized medicine: A model of incentives for value creation and capture. Drug Inf. J. 41:501-509.
22. Garrison, L. P., Jr., Veenstra, D. L., Carlson, R., Carlson, J., Meckley, L. (2007). Backgrounder on pharmacogenomics for the pharmaceutical and biotechnology industries: Basic science, future scenarios, policy directions: University of Washington.
23. Genentech, I. (2005). Herceptin (trastuzumab) [full prescribing information]. South San Francisco, CA: Genentech, Inc.
24. Goleman, D. (1996, Nov. 19). Research on brain leads to pursuit of designer drugs. The New York Times.
25. Hales, D. (2004, Sep 19). Treatment tailor-made for you. Parade, 4-6.
26. Holtzman, N. (2000). FDA and the regulation of genetic tests. Jurimetrics 41:53-62.
27. Holtzman, N. A., Watson, M. S. (1997). Promoting safe and effective genetic testing in the United States. In Health and Human Services (Ed.).
28. Human Genome Program U.S. Department of Energy. (2000). Gene patenting update: U.S. PTO tightens requirements. Retrieved 2/12/2007 from http://www.ornl.gov/sci/techresources/Human_Genome/publicat/hgn/v11n1/09patent. shtml
29. Human Genome Program U.S. Department of Energy. (2006). Human genome project information: Genetics and patenting. Retrieved 9/11/2007 from http://www.ornl.gov/sci/techresources/Human_Genome/elsi/patents.shtml.
30. Issa, A. M. (2002). Ethical perspectives on pharmacogenomic profiling in the drug development process. Nature Reviews Drug Discovery 1:300.
31. Johnson v. Kokemoor, 545 N.W.2d 495 (Wis. 1996).
32. Kaplan, W. (2004). Biotech patenting 101. Retrieved 2/15/06, 2006, from http://www.gene-watch.org/programs/patents/patenting101.html.
33. Maeder, T. (2003). The orphan drug backlash. Sci. Am. 288:80-87.
34. Marshall, E. (2003). Preventing toxicity with a gene test. Science 302:588-590.
35. Meadows, M. (2001). The power of Accutane: The benefits and risks of a breakthrough acne drug. FDA Consumer magazine. US Food and Drug Administration. March-April 2001, http://www.fda.gov/fdac/features/2001/ 201_acne.html
36. Miesfeldt, S., Jones, S. M., Cohn, W. F. (2000). Informed consent for BRCA1 and BRCA2 testing: What clinicians should know about the process and content. J Am Med Womens Assoc 55:275-279.
37. Ojha, R. P., Thertulien, R. (2005). Health care policy issues as a result of the genetic revolution: Implications for public health. Am. J. Public Health 95:385-388.
38. Pate v. Threlkel, 661 So.2d 278 (Fla. 1995).
39. Perez v. Wyeth Laboratories, Inc. 734 A.2d 1245 (N.J. 1999).
40. Poirier, J. (1999). Apolipoprotein e: A pharmacogenetic target for the treatment of Alzheimer's disease. Mol. Diagn. 4:335-341.
41. Rai, A. K. (2002). Pharmacogenetic interventions, orphan drugs, and distributive justice: The role of cost-benefit analysis. Soc Philos Policy 19:246-270.
42. Regalado, A. (2002). The great gene grab, Technol. Rev. September/October 2000, pp. 49-55.
43. Robertson, J. A. (2001). Consent and privacy in pharmacogenetic testing. Nat. Genet. 28:207.
44. Robertson, J. A., Brody, B., Buchanan, A., Kahn, J., McPherson, E. (2002). Pharmacogenetic challenges for the health care system. Health Aff 21:155-167.
45. Safer v. Estate of Pack, 677 A.2d 1188 (N.J. Super. 1996).
46. Salgo v. Leland Stanford Jr. Univ. Bd. of Trustees, 317 P.2d 170 (Cal. App. 1957).
47. Schloendorff v. Soc. of N.Y. Hosp., 105 N.E. 92 (NY 1914).
48. Schubert, L. (2004). Ethical implications of pharmacogenetics - do slippery slope arguments matter? Bioethics 18:361-378.
49. Secretary's Advisory Committee on Genetics Testing. (2000). Enhancing the oversight of genetic tests: Recommendations of the SACGT. Retrieved 2/15/06 from http://www4.od.nih.gov/oba/sacgt/reports/oversight_report.pdf.
50. Shah, J. (2003). Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare. Nat. Biotechnol. 21:747-753.
51. Shi, M. M., Bleavins, M. R., de la Iglesia, F. A. (2001). Pharmacogenetic application in drug development and clinical trials. Drug Metab. Dispos. 29:591-595.
52. Smart, A., Martin, P., Parker, M. (2004). Tailored medicine: Whom will it fit? The ethics of patient and disease stratification. Bioethics 18:322-342.
53. Specific requirements on content and format of labeling for human prescription drugs, 21 CFR § 201.56 (2001).
54. The Lewin Group. (2005). The value of diagnostics innovation, adoption and diffusion into health care. Retrieved 8/31/2005 from http://www.advamed.org/ publicdocs/thevalueofdiagnostics. pdf.
55. Twerski, A. D. (1999). The second revolution in informed consent: Comparing physicians to each other. NW U. L. Rev. 94: 1.
56. U.S. Department of Health and Human Services. (1998). Clinical laboratory improvement advisory committee summary report.
57. Wainberg, S., Husted, J. (2004). Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol. Biomarkers Prev. 13:1989-1995.